Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options
- PMID: 33031623
- PMCID: PMC7675336
- DOI: 10.1002/cbic.202000595
Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options
Abstract
The human world is currently influenced largely by the outbreak of pandemic COVID-19. At this moment, most researchers focus on developing treatment strategies and measures to work against COVID-19. Treatment strategies specific for COVID-19 are lacking. This article provides an overview of the life cycle and routes of transmission of SARS-CoV-2. The therapeutic effects of two drugs [i. e., remdesivir (RDV) and favipiravir (FPV)] which can potentially tackle COVID-19 are discussed based on current published data. This review can serve as a reference for future studies.
Keywords: COVID-19; favipiravir; pandemic; remdesivir; routes of transmission.
© 2020 Wiley-VCH GmbH.
Conflict of interest statement
The authors declare no conflict of interests. This research did not receive any specific grant from funding agencies in the public, commercial, or not‐for‐profit sectors.
Figures


Similar articles
-
Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.Cardiovasc Hematol Disord Drug Targets. 2021;21(2):88-90. doi: 10.2174/1871529X21666210812103535. Cardiovasc Hematol Disord Drug Targets. 2021. PMID: 34387172
-
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.Biomed Pharmacother. 2022 Mar;147:112700. doi: 10.1016/j.biopha.2022.112700. Epub 2022 Feb 4. Biomed Pharmacother. 2022. PMID: 35131656 Free PMC article. Review.
-
Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.Mini Rev Med Chem. 2022;22(2):232-247. doi: 10.2174/1389557521666210712205655. Mini Rev Med Chem. 2022. PMID: 34254915 Review.
-
Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters.Viruses. 2024 Nov 27;16(12):1838. doi: 10.3390/v16121838. Viruses. 2024. PMID: 39772148 Free PMC article.
-
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.EMBO Mol Med. 2021 Jan 11;13(1):e13105. doi: 10.15252/emmm.202013105. Epub 2020 Nov 3. EMBO Mol Med. 2021. PMID: 33015938 Free PMC article. Review.
Cited by
-
Novel Polymorph of Favipiravir-An Antiviral Medication.Pharmaceutics. 2021 Jan 21;13(2):139. doi: 10.3390/pharmaceutics13020139. Pharmaceutics. 2021. PMID: 33494498 Free PMC article.
-
Global landscape of patents related to human coronaviruses.Int J Biol Sci. 2021 Apr 10;17(6):1588-1599. doi: 10.7150/ijbs.58807. eCollection 2021. Int J Biol Sci. 2021. PMID: 33907523 Free PMC article. Review.
-
Inhibition of SARS-CoV-2 3CL protease by the anti-viral chimeric protein RetroMAD1.Sci Rep. 2023 Nov 17;13(1):20178. doi: 10.1038/s41598-023-47511-z. Sci Rep. 2023. PMID: 37978223 Free PMC article.
-
Repurposing dyphylline as a pan-coronavirus antiviral therapy.Future Med Chem. 2022 May;14(10):685-699. doi: 10.4155/fmc-2021-0311. Epub 2022 Apr 7. Future Med Chem. 2022. PMID: 35387498 Free PMC article.
-
Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline.Pharmaceutics. 2022 Jan 27;14(2):300. doi: 10.3390/pharmaceutics14020300. Pharmaceutics. 2022. PMID: 35214034 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous